Covidien PLC, a provider of healthcare products, has launched a new catheter for the treatment of Barrett's esophagus and other specific gastrointestinal bleeding disorders in the United States and Europe.The Dublin-based'pany, with U.S. headquarters in Mansfield, Mass., on Tuesday launched the Barrx Channel RFA Endoscopic Catheter. When Barretts esophagus, a precancerous condition of the esophageal lining that is a'plication of gastroesophogeal reflux disease, is left untreated, it can lead to cancer of the esophagus.
According to Covidien, its Barrx line of catheters is based on technology that controls the amount of RF radio frequency energy delivered during a procedure to remove diseased tissue, leaving the healthy tissue untouched. By using the catheter, doctors can shorten the time of procedures because the new design allows for few endoscope introductions and removals, according to Covidien."Covidien continues to offer patients and physicians a solution to address Barrett's esophagus," said Vafa Jamali, vice president and general manager of GI Solutions at Covidien. "The newest addition to the Barrx portfolio is designed to simplify the procedure by delivering our proven RF technology through the working channel of the endoscope.
"Our increasing reliance on implantable devices such as catheters and stents,'bined with the rapid evolution of antibiotic resistant strains of bacteria has created a challenge for the medical'munity.The covalent immobilisation of antimicrobial peptides on the surface of devices to give them an antimicrobial coating has been suggested many times before. However, host cell toxicity and reduced activity following sub-optimal immobilisation strategies often hinder the success of immobilised AMPs.
沒有留言:
張貼留言